BSE Live
Dec 31, 13:26Prev. Close
388.45
Open Price
388.75
Bid Price (Qty.)
382.40 (25)
Offer Price (Qty.)
383.25 (341)
NSE Live
Dec 31, 13:26Prev. Close
386.55
Open Price
388.00
Bid Price (Qty.)
382.65 (148)
Offer Price (Qty.)
383.05 (190)
| Balance Sheet of Panacea Biotec (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 | |
| Total Share Capital | 9.02 | 16.67 | 15.59 | 14.61 | 22.43 | |
| Reserves and Surplus | 138.87 | 334.63 | 292.91 | 339.91 | 426.18 | |
| Total Reserves and Surplus | 138.87 | 334.63 | 292.91 | 339.91 | 426.18 | |
| Total Shareholders Funds | 179.89 | 351.30 | 308.50 | 354.52 | 448.61 | |
| Minority Interest | -3.04 | -3.01 | -2.95 | 10.54 | 1.08 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 610.23 | 35.58 | 561.25 | 705.57 | 867.08 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 9.26 | 11.09 | 0.50 | |
| Other Long Term Liabilities | 83.48 | 3.97 | 4.29 | 4.77 | 48.11 | |
| Long Term Provisions | 42.74 | 39.78 | 26.54 | 18.36 | 14.23 | |
| Total Non-Current Liabilities | 736.45 | 79.33 | 601.34 | 739.79 | 929.92 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 3.57 | 69.39 | 164.89 | 190.71 | 191.82 | |
| Trade Payables | 198.85 | 269.71 | 277.20 | 248.60 | 187.87 | |
| Other Current Liabilities | 245.83 | 592.72 | 242.01 | 237.53 | 93.60 | |
| Short Term Provisions | 6.96 | 6.44 | 6.94 | 8.80 | 1.51 | |
| Total Current Liabilities | 455.21 | 938.26 | 691.03 | 685.64 | 474.80 | |
| Total Capital And Liabilities | 1,390.30 | 1,375.52 | 1,607.56 | 1,800.14 | 1,854.41 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 655.52 | 803.11 | 942.88 | 993.62 | 1,052.08 | |
| Intangible Assets | 1.86 | 2.46 | 5.20 | 6.86 | 19.03 | |
| Capital Work-In-Progress | 9.51 | 8.39 | 7.52 | 8.70 | 150.59 | |
| Fixed Assets | 681.39 | 828.07 | 988.00 | 1,030.88 | 1,232.06 | |
| Non-Current Investments | 5.58 | 5.33 | 5.25 | 7.01 | 5.19 | |
| Deferred Tax Assets [Net] | 1.95 | 19.79 | 19.66 | 29.50 | 0.00 | |
| Long Term Loans And Advances | 1.21 | 1.17 | 1.04 | 1.05 | 68.01 | |
| Other Non-Current Assets | 16.90 | 13.28 | 32.36 | 31.07 | 0.56 | |
| Total Non-Current Assets | 707.03 | 867.63 | 1,047.21 | 1,100.41 | 1,305.82 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 2.03 | 0.27 | 3.52 | |
| Inventories | 147.69 | 81.43 | 334.21 | 315.55 | 305.24 | |
| Trade Receivables | 68.52 | 88.73 | 136.01 | 142.17 | 141.67 | |
| Cash And Cash Equivalents | 89.75 | 23.48 | 23.24 | 14.13 | 22.93 | |
| Short Term Loans And Advances | 4.36 | 18.13 | 35.31 | 10.48 | 69.63 | |
| OtherCurrentAssets | 372.96 | 296.12 | 29.55 | 217.12 | 5.60 | |
| Total Current Assets | 683.27 | 507.89 | 560.35 | 699.73 | 548.59 | |
| Total Assets | 1,390.30 | 1,375.52 | 1,607.56 | 1,800.14 | 1,854.41 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 368.66 | 407.73 | 428.11 | 0.00 | 459.98 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 1.81 | 1.81 | 1.81 | 1.81 | 1.81 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 1.88 | 0.01 | |
| Non-Current Investments Unquoted Book Value | 0.07 | 0.07 | 0.07 | 0.07 | 5.18 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 2.03 | 0.27 | 3.52 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
26.12.2025
16.12.2025
27.11.2025
26.11.2025
Panacea Biotec Consolidated September 2025 Net Sales at Rs 141.13 crore, down 4.22% Y-o-Y
26.11.2025
Panacea Biotec Consolidated September 2025 Net Sales at Rs 141.13 crore, down 4.22% Y-o-Y
24.11.2025
Panacea Biotec Standalone September 2025 Net Sales at Rs 90.81 crore, up 18.49% Y-o-Y
11.06.2025
Panacea Biotec Standalone March 2025 Net Sales at Rs 67.90 crore, down 15.52% Y-o-Y
03.06.2025
Panacea Biotec Consolidated March 2025 Net Sales at Rs 132.53 crore, down 2.88% Y-o-Y